These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

635 related items for PubMed ID: 15708050

  • 41. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
    Berger AP, Deibl M, Steiner H, Bektic J, Pelzer A, Spranger R, Klocker H, Bartsch G, Horninger W.
    Prostate; 2005 Aug 01; 64(3):240-5. PubMed ID: 15712213
    [Abstract] [Full Text] [Related]

  • 42. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.
    Schröder FH, Roobol MJ.
    Curr Opin Urol; 2009 May 01; 19(3):227-31. PubMed ID: 19357513
    [Abstract] [Full Text] [Related]

  • 43. Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam.
    van der Cruijsen-Koeter IW, Roobol MJ, Wildhagen MF, van der Kwast TH, Kirkels WJ, Schröder FH.
    Urology; 2006 Sep 01; 68(3):615-20. PubMed ID: 17010732
    [Abstract] [Full Text] [Related]

  • 44. A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam).
    Roobol MJ, Schröder FH, Kranse R, ERSPC, Rotterdam.
    Prostate; 2006 May 01; 66(6):604-12. PubMed ID: 16388508
    [Abstract] [Full Text] [Related]

  • 45. Prospective longitudinal evaluation of men with initial prostate specific antigen levels of 4.0 ng./ml. or less.
    Harris CH, Dalkin BL, Martin E, Marx PC, Ahmann FR.
    J Urol; 1997 May 01; 157(5):1740-3. PubMed ID: 9112517
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer.
    Naya Y, Fritsche HA, Bhadkamkar VA, Mikolajczyk SD, Rittenhouse HG, Babaian RJ.
    Urology; 2004 Mar 01; 63(3):492-8. PubMed ID: 15028444
    [Abstract] [Full Text] [Related]

  • 48. Large-scale study of clinical impact of PSA velocity: long-term PSA kinetics as method of differentiating men with from those without prostate cancer.
    Berger AP, Deibl M, Strasak A, Bektic J, Pelzer AE, Klocker H, Steiner H, Fritsche G, Bartsch G, Horninger W.
    Urology; 2007 Jan 01; 69(1):134-8. PubMed ID: 17270635
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Prostate cancer detection in men with a 'normal' total prostate-specific antigen (PSA) level using percentage free PSA: a prospective screening study.
    Rowe EW, Laniado ME, Walker MM, Patel A.
    BJU Int; 2005 Jun 01; 95(9):1249-52. PubMed ID: 15892810
    [Abstract] [Full Text] [Related]

  • 55. Prostate-specific antigen velocity and prostate cancer gleason grade and stage.
    Pinsky PF, Andriole G, Crawford ED, Chia D, Kramer BS, Grubb R, Greenlee R, Gohagan JK.
    Cancer; 2007 Apr 15; 109(8):1689-95. PubMed ID: 17330856
    [Abstract] [Full Text] [Related]

  • 56. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
    van Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A, Bangma CH, Schröder FH.
    Eur J Cancer; 2010 Jan 15; 46(2):377-83. PubMed ID: 19804966
    [Abstract] [Full Text] [Related]

  • 57. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.
    Chun FK, Hutterer GC, Perrotte P, Gallina A, Valiquette L, Benard F, McCormack M, Briganti A, Ionescu C, Jeldres C, Guay JP, Saad F, Karakiewicz PI.
    BJU Int; 2007 Jul 15; 100(1):37-41. PubMed ID: 17488305
    [Abstract] [Full Text] [Related]

  • 58. Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen.
    Labrie F, Candas B, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M.
    Urology; 1996 Feb 15; 47(2):212-7. PubMed ID: 8607237
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
    Loeb S, Roehl KA, Antenor JA, Catalona WJ, Suarez BK, Nadler RB.
    Urology; 2006 Feb 15; 67(2):316-20. PubMed ID: 16442597
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 32.